Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

171 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase I study of talazoparib (BMN 673) combined with carboplatin and paclitaxel in patients with advanced solid tumors (NCI9782).
Leal TA, Sharifi MN, Chan N, Wesolowski R, Turk AA, Bruce JY, O'Regan RM, Eickhoff J, Barroilhet LM, Malhotra J, Mehnert J, Girda E, Wiley E, Schmitz N, Andrews S, Liu G, Wisinski KB. Leal TA, et al. Among authors: wesolowski r. Cancer Med. 2022 Nov;11(21):3969-3981. doi: 10.1002/cam4.4724. Epub 2022 Apr 8. Cancer Med. 2022. PMID: 35396812 Free PMC article. Clinical Trial.
Incidence, Clinicopathologic Features, HER2 Fluorescence In Situ Hybridization Profile, and Oncotype DX Results of Human Epidermal Growth Factor Receptor 2-Low Breast Cancers: Experience From a Single Academic Center.
Hu Y, Jones D, Zhao W, Tozbikian G, Wesolowski R, Parwani AV, Li Z. Hu Y, et al. Among authors: wesolowski r. Mod Pathol. 2023 Jul;36(7):100164. doi: 10.1016/j.modpat.2023.100164. Epub 2023 Mar 24. Mod Pathol. 2023. PMID: 36967073 Free article.
Phase I Immunotherapy Trial with Two Chimeric HER-2 B-Cell Peptide Vaccines Emulsified in Montanide ISA 720VG and Nor-MDP Adjuvant in Patients with Advanced Solid Tumors.
Bekaii-Saab T, Wesolowski R, Ahn DH, Wu C, Mortazavi A, Lustberg M, Ramaswamy B, Fowler J, Wei L, Overholser J, Kaumaya PTP. Bekaii-Saab T, et al. Among authors: wesolowski r. Clin Cancer Res. 2019 Jun 15;25(12):3495-3507. doi: 10.1158/1078-0432.CCR-18-3997. Epub 2019 Feb 25. Clin Cancer Res. 2019. PMID: 30804020 Free PMC article. Clinical Trial.
Making National Cancer Institute-Designated Comprehensive Cancer Center Knowledge Accessible to Community Oncologists via an Online Tumor Board: Longitudinal Observational Study.
Kalra M, Henry E, McCann K, Karuturi MS, Bustamante Alvarez JG, Parkes A, Wesolowski R, Wei M, Mougalian SS, Durm G, Qin A, Schonewolf C, Trivedi M, Armaghani AJ, Wilson FH, Iams WT, Turk AA, Vikas P, Cecchini M, Lubner S, Pathak P, Spencer K, Koshkin VS, Labriola MK, Marshall CH, Beckermann KE; theMednet.org NCI-CCC Tumor Board Program Collaborative Group; Sharifi MN, Bejjani AC, Hotchandani V, Housri S, Housri N. Kalra M, et al. Among authors: wesolowski r. JMIR Cancer. 2022 May 19;8(2):e33859. doi: 10.2196/33859. JMIR Cancer. 2022. PMID: 35588361 Free PMC article.
First-in-human phase I/Ib study of NIZ985, a recombinant heterodimer of IL-15 and IL-15Rα, as a single agent and in combination with spartalizumab in patients with advanced and metastatic solid tumors.
Leidner R, Conlon K, McNeel DG, Wang-Gillam A, Gupta S, Wesolowski R, Chaudhari M, Hassounah N, Lee JB, Ho Lee L, O'Keeffe JA, Lewis N, Pavlakis GN, Thompson JA. Leidner R, et al. Among authors: wesolowski r. J Immunother Cancer. 2023 Oct;11(10):e007725. doi: 10.1136/jitc-2023-007725. J Immunother Cancer. 2023. PMID: 37907221 Free PMC article. Clinical Trial.
An Open-Label Study of Subcutaneous CpG Oligodeoxynucleotide (PF03512676) in Combination with Trastuzumab in Patients with Metastatic HER2+ Breast Cancer.
Quiroga D, Wesolowski R, Zelinskas S, Pinette A, Benner B, Schwarz E, Savardekar H, Johnson C, Stiff A, Yu L, Macrae E, Lustberg M, Mrozek E, Ramaswamy B, Carson WE 3rd. Quiroga D, et al. Among authors: wesolowski r. Cancer Control. 2024 Jan-Dec;31:10732748241250189. doi: 10.1177/10732748241250189. Cancer Control. 2024. PMID: 38797949 Free PMC article. Clinical Trial.
Real-world treatment patterns of adjuvant endocrine therapy and ovarian suppression in premenopausal HR+/HER2+ breast cancer.
Sukumar JS, Sardesai S, Ni A, Williams N, Johnson K, Quiroga D, Ramaswamy B, Wesolowski R, Cherian M, Stover DG, Gatti-Mays M, Pariser A, Sudheendra P, George MA, Lustberg M. Sukumar JS, et al. Among authors: wesolowski r. Cancer Med. 2024 Jun;13(12):e7317. doi: 10.1002/cam4.7317. Cancer Med. 2024. PMID: 38895891 Free PMC article.
171 results